Wetherby Asset Management Inc Vertex Pharmaceuticals Inc Transaction History

Wetherby Asset Management Inc

$2.04 Billion
Q4 2024

A detailed history of Wetherby Asset Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wetherby Asset Management Inc holds 5,582 shares of VRTX stock, worth $2.48 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

5,582

Previous 5,879 5.05%

Holding current value

$2.48 Million

Previous $2.73 Million 17.81%

% of portfolio

0.11%

Previous 0.13%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$396.64 - $516.74 $117,802 - $153,471	-297 Reduced 5.05%	5,582 $2.25 Million
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $38,640 - $42,485	-84 Reduced 1.41%	5,879 $2.73 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $11,784 - $14,565	30 Added 0.51%	5,963 $2.79 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $5,299 - $5,799	-13 Reduced 0.22%	5,933 $2.48 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $4,802 - $5,749	14 Added 0.24%	5,946 $2.42 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $36,185 - $38,783	107 Added 1.84%	5,932 $2.06 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $56,281 - $62,991	-179 Reduced 2.98%	5,825 $2.05 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $60,327 - $68,820	213 Added 3.68%	6,004 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $12,287 - $13,823	43 Added 0.75%	5,791 $1.67 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $147,868 - $164,986	540 Added 10.37%	5,748 $1.66 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $104,557 - $130,184	-445 Reduced 7.87%	5,208 $1.47 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $94,103 - $110,912	425 Added 8.13%	5,653 $1.48 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $203,207 - $256,520	1,148 Added 28.14%	5,228 $1.15 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $59,314 - $66,377	-327 Reduced 7.42%	4,080 $740,000
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $73,121 - $86,229	-390 Reduced 8.13%	4,407 $889,000
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $60,035 - $69,979	-290 Reduced 5.7%	4,797 $1.03 Million
Q4 2020 Feb 11, 2021	BUY	$207.01 - $276.09 $965,080 - $1.29 Million	4,662 Added 1096.94%	5,087 $1.2 Million
Q3 2020 Dec 16, 2020	SELL	$255.65 - $303.1 $1.22 Million - $1.44 Million	-4,754 Reduced 91.79%	425 $116,000
Q3 2020 Dec 16, 2020	SELL	$255.65 - $303.1 $113,508 - $134,576	-444 Reduced 7.9%	5,179 $1.41 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $24,798 - $29,400	-97 Reduced 1.7%	5,623 $1.53 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $14,656 - $19,227	65 Added 1.15%	5,720 $1.66 Million
Q1 2020 May 06, 2020	BUY	$199.77 - $247.81 $89,696 - $111,266	449 Added 8.62%	5,655 $1.35 Million
Q4 2019 Jan 28, 2020	BUY	$166.71 - $223.91 $29,507 - $39,632	177 Added 3.52%	5,206 $1.14 Million
Q3 2019 Oct 31, 2019	BUY	$166.23 - $187.09 $43,219 - $48,643	260 Added 5.45%	5,029 $852,000
Q2 2019 Jul 25, 2019	BUY	$164.61 - $190.37 $13,662 - $15,800	83 Added 1.77%	4,769 $874,000
Q1 2019 May 09, 2019	BUY	$163.73 - $194.7 $22,431 - $26,673	137 Added 3.01%	4,686 $862,000
Q4 2018 Jan 30, 2019	BUY	$151.91 - $192.21 $45,117 - $57,086	297 Added 6.98%	4,549 $754,000
Q3 2018 Nov 07, 2018	BUY	$167.73 - $192.74 $37,739 - $43,366	225 Added 5.59%	4,252 $820,000
Q2 2018 Jul 24, 2018	SELL	$145.72 - $169.96 $7,431 - $8,667	-51 Reduced 1.25%	4,027 $684,000
Q1 2018 May 04, 2018	BUY	$151.6 - $177.13 $56,850 - $66,423	375 Added 10.13%	4,078 $665,000
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $8,511 - $9,644	62 Added 1.7%	3,703 $555,000
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $539,341 - $590,715	3,641	3,641 $554,000

Others Institutions Holding VRTX

# of Institutions

1,832

Shares Held

233M

Call Options Held

1.38M

Put Options Held

1.08M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $114B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.

Account

Wetherby Asset Management Inc Vertex Pharmaceuticals Inc Transaction History